Immunocore Holdings plc Interest Expense Nonoperating
Immunocore Holdings plc (IMCR) reported Interest Expense Nonoperating of $3.06 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-06
- Immunocore Holdings plc interest expense nonoperating for the quarter ending 2026-06-30 was $3.06M, a 0.56% increase year-over-year.
- Immunocore Holdings plc interest expense nonoperating for the quarter ending 2026-03-31 was $3.05M, a 0.86% increase year-over-year.
- Immunocore Holdings plc interest expense nonoperating for the quarter ending 2025-12-31 was $3.05M, a 56.62% decline year-over-year.
- Immunocore Holdings plc interest expense nonoperating for the quarter ending 2025-09-30 was $3.04M, a 29.07% decline year-over-year.
- Immunocore Holdings plc interest expense nonoperating for fiscal 2025 was $12.17M, a 35.44% decline from fiscal 2024.
- Immunocore Holdings plc interest expense nonoperating for fiscal 2024 was $18.84M, a 265.62% increase from fiscal 2023.
- Immunocore Holdings plc interest expense nonoperating for fiscal 2023 was $5.15M, a 4.71% decline from fiscal 2022.
- Immunocore Holdings plc interest expense nonoperating for fiscal 2022 was $5.41M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.06M 10-Q · filed 2026-08-06 | $6.11M 10-Q · filed 2026-08-06 | $9.17M derived: sum of 3 quarters · filed 2026-08-06 | $12.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $3.05M 10-Q · filed 2026-05-06 | $6.10M derived: sum of 2 quarters · filed 2026-05-06 | $9.15M derived: sum of 3 quarters · filed 2026-05-06 | $12.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.05M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.10M derived: sum of 2 quarters · filed 2026-02-25 | $9.14M derived: sum of 3 quarters · filed 2026-08-06 | $12.17M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.04M 10-Q · filed 2025-11-06 | $6.09M derived: sum of 2 quarters · filed 2026-08-06 | $9.11M 10-Q · filed 2025-11-06 | $16.15M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.04M 10-Q · filed 2026-08-06 | $6.07M 10-Q · filed 2026-08-06 | $13.11M derived: sum of 3 quarters · filed 2026-08-06 | $17.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $3.02M 10-Q · filed 2026-05-06 | $10.06M derived: sum of 2 quarters · filed 2026-05-06 | $14.35M derived: sum of 3 quarters · filed 2026-05-06 | $18.63M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $11.33M derived: sum of 2 quarters · filed 2026-02-25 | $15.61M derived: sum of 3 quarters · filed 2026-02-25 | $18.84M 10-K · filed 2026-02-25 |
| 2024-09-30 | $4.29M 10-Q · filed 2025-11-06 | $8.57M derived: sum of 2 quarters · filed 2025-11-06 | $11.81M 10-Q · filed 2025-11-06 | $13.12M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $4.28M 10-Q · filed 2025-08-07 | $7.52M 10-Q · filed 2025-08-07 | $8.82M derived: sum of 3 quarters · filed 2026-02-25 | $10.15M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $3.24M 10-Q · filed 2025-05-07 | $4.55M derived: sum of 2 quarters · filed 2026-02-25 | $5.87M derived: sum of 3 quarters · filed 2026-02-25 | $7.14M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $1.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $2.63M derived: sum of 2 quarters · filed 2026-02-25 | $3.90M derived: sum of 3 quarters · filed 2026-02-25 | $5.15M 10-K · filed 2026-02-25 |
| 2023-09-30 | $1.32M 10-Q · filed 2024-11-06 | $2.60M derived: sum of 2 quarters · filed 2024-11-06 | $3.85M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $1.27M 10-Q · filed 2024-08-08 | $2.52M 10-Q · filed 2024-08-08 | ||
| 2022-12-31 | $5.41M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |